Patent classifications
C07C69/017
Biologically active cannabidiol analogs
Biologically active cannabidiol analogs comprising a compound of the formula ##STR00001##
wherein one of R.sub.1 or R.sub.2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R.sub.1 or R.sub.2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R.sub.1 or R.sub.2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.
MACROMOLECULAR CORROSION (MCIN) INHIBITORS: STRUCTURES, METHODS OF MAKING AND USING THE SAME
Disclosed are multifunctional compounds represented by structural formula (I):
##STR00001##
methods of producing compounds represented by structural formula (I) and their use in inhibiting corrosion in corrodible material.
MACROMOLECULAR CORROSION (MCIN) INHIBITORS: STRUCTURES, METHODS OF MAKING AND USING THE SAME
Disclosed are multifunctional compounds represented by structural formula (I):
##STR00001##
methods of producing compounds represented by structural formula (I) and their use in inhibiting corrosion in corrodible material.
Compositions of polyhydroxylated benzophenones and methods of treatment of neurodegenerative disorders
The present invention relates to polyhydroxylated benzophenone compounds useful in the treatment of neurodegenerative, neurological, psychiatric, and cognitive diseases, in particular those associated with a deficiency in HDAC1 deacetylase activity.
Compositions of polyhydroxylated benzophenones and methods of treatment of neurodegenerative disorders
The present invention relates to polyhydroxylated benzophenone compounds useful in the treatment of neurodegenerative, neurological, psychiatric, and cognitive diseases, in particular those associated with a deficiency in HDAC1 deacetylase activity.
POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT
Provided is a polar compound having high chemical stability, high capability of aligning liquid crystal molecules, high solubility in a liquid crystal composition, and a large voltage holding ratio when used in a liquid crystal display device. The compound is represented by formula (1):
##STR00001##
in which, for example, R.sup.1 is alkyl having 1 to 15 carbons; MES is a mesogen group having at least one ring; Sp.sup.1 is a single bond or alkylene having 1 to 10 carbons; M.sup.1 and M.sup.2 are hydrogen; and R.sup.2 is a group represented by formulas (1a) to (1c):
##STR00002##
in which, Sp.sup.2 and Sp.sup.a are a single bond or alkylene having 1 to 10 carbons; S.sup.1 is >CH—; S.sup.2 is >C<; and X.sup.1 is —OH.
POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT
Provided is a polar compound having high chemical stability, high capability of aligning liquid crystal molecules, high solubility in a liquid crystal composition, and a large voltage holding ratio when used in a liquid crystal display device. The compound is represented by formula (1):
##STR00001##
in which, for example, R.sup.1 is alkyl having 1 to 15 carbons; MES is a mesogen group having at least one ring; Sp.sup.1 is a single bond or alkylene having 1 to 10 carbons; M.sup.1 and M.sup.2 are hydrogen; and R.sup.2 is a group represented by formulas (1a) to (1c):
##STR00002##
in which, Sp.sup.2 and Sp.sup.a are a single bond or alkylene having 1 to 10 carbons; S.sup.1 is >CH—; S.sup.2 is >C<; and X.sup.1 is —OH.
BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA
The invention relates to bimesogenic compounds of formula I
##STR00001##
wherein R.sup.11, R.sup.12, MG.sup.11, MG.sup.12, X.sup.11, X.sup.12 and Sp.sup.1 have the meaning given in claim 1, to the use of bimesogenic compounds of formula I in liquid crystal media and particular to flexoelectric liquid crystal devices comprising a liquid crystal medium according to the present invention.
BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA
The invention relates to bimesogenic compounds of formula I
##STR00001##
wherein R.sup.11, R.sup.12, MG.sup.11, MG.sup.12, X.sup.11, X.sup.12 and Sp.sup.1 have the meaning given in claim 1, to the use of bimesogenic compounds of formula I in liquid crystal media and particular to flexoelectric liquid crystal devices comprising a liquid crystal medium according to the present invention.
Menaquinol Compositions and Methods of Treatment
The present application discloses methods for the efficient preparation of high purity compounds of the Formula I, and their methods of use.
##STR00001##